A Lower Dose of Melphalan (140 mg/m2) As Preparative Regimen for Multiple Myeloma in Patients >65 or with Renal Dysfunction

被引：2
|
作者：
Saunders, Ila Maewal [1 ]
Gulbis, Alison [1 ]
Champlin, Richard E. [2 ]
Qazilbash, Muzaffar H. [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2014年 / 20卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2013.12.496
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
459
引用
收藏
页码：S293 / S294
页数：2
相关论文
共 50 条
  • [1] A Lower Dose Of Melphalan (140 mg/m2) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction
    Saunders, Ila Maewal
    Gulbis, Alison M.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD, 2013, 122 (21)
  • [2] COMPARISON OF BUSULFAN plus MELPHALAN TO MELPHALAN 200 MG/M2 AS PREPARATIVE REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA
    Ahmed, S.
    Dinh, Y.
    Rondon, G.
    Andersson, B.
    Jones, R.
    Bashir, Q.
    Shah, N.
    Popat, U.
    Champlin, R. E.
    Qazilbash, M. H.
    Kebriaei, P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S251 - S251
  • [3] A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT
    W I Bensinger
    P S Becker
    T A Gooley
    T R Chauncey
    D G Maloney
    A K Gopal
    D J Green
    O W Press
    M Lill
    J J Ifthikharuddin
    R Vescio
    L A Holmberg
    G L Phillips
    Bone Marrow Transplantation, 2016, 51 : 67 - 71
  • [4] A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT
    Bensinger, W. I.
    Becker, P. S.
    Gooley, T. A.
    Chauncey, T. R.
    Maloney, D. G.
    Gopal, A. K.
    Green, D. J.
    Press, O. W.
    Lill, M.
    Ifthikharuddin, J. J.
    Vescio, R.
    Holmberg, L. A.
    Phillips, G. L.
    BONE MARROW TRANSPLANTATION, 2016, 51 (01) : 67 - 71
  • [5] Randomized Comparison of Melphalan 200 Mg/m2 v. 280 Mg/m2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
    Bensinger, William I.
    Becker, Pamela S.
    Gooley, Ted A.
    Chauncey, Thomas
    Maloney, David G.
    Vescio, Robert
    Gopal, Ajay K.
    Green, Damian J.
    Press, Oliver W.
    Lill, Michael
    Holmberg, Leona
    Ifthikharuddin, Jainulabdeen J.
    Phillips, Gordon L., II
    BLOOD, 2012, 120 (21)
  • [6] Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma
    Sharma, Nidhi
    Benson, Evan
    Zhao, Qiuhong
    Nunnelee, Jordan
    Cottini, Francesca
    Elder, Patrick
    Rosko, Ashley
    Bumma, Naresh
    Khan, Abdullah
    Umyarova, Elvira
    Devarakonda, Srinivas
    Efebera, Yvonne A. A.
    Benson, Don M. M.
    LEUKEMIA & LYMPHOMA, 2023, 64 (07) : 1315 - 1321
  • [7] Double Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma
    Ludwig, Heinz
    Spicka, Ivan
    Linkesch, Werner
    Greil, Richard
    Kasparu, Hedwig
    Gunsilius, Eberhard
    Thaler, Josef
    Drach, Johannes
    Kuhn, Ingrid
    Weissmann, Adalbert
    Hinke, Axel
    BLOOD, 2008, 112 (11) : 1139 - 1139
  • [8] Dose-intensive melphalan regimens (100 mg/m2 versus 200 mg/m2) in multiple myeloma patients.
    Boccadoro, M
    Bringhen, S
    Cavallo, F
    Falco, P
    Bertola, A
    Barbui, A
    Caravita, T
    Musto, P
    Pescosta, N
    Vignetti, M
    Palumbo, A
    BLOOD, 2002, 100 (11) : 431A - 431A
  • [9] Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure
    Vigneau, C
    Ardiet, C
    Bret, M
    Laville, M
    Fiere, D
    Tranchand, B
    Fouque, D
    JOURNAL OF NEPHROLOGY, 2002, 15 (06) : 684 - 689
  • [10] Reduced-dose carmustine (300 mg/m2) and melphalan as a conditioning regimen in multiple myeloma patients with CNS involvement: A case series
    Rueda, Garrett
    Smith, Eric
    De Padova, Nicolas
    Heers, Hayley
    Komerdelj, Ivan
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 12
12345